AbbVie Inc. $ABBV Shares Sold by Kellett Wealth Advisors LLC

14 Oct 2025, 12:34 by Mitch Edgeman · The Markets Daily

Kellett Wealth Advisors LLC trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 17.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,268 shares of the company’s stock after selling 667 shares during the quarter. Kellett Wealth Advisors LLC’s holdings in AbbVie were worth $607,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in ABBV. TD Capital Management LLC increased its position in AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after acquiring an additional 58 shares during the period. Marshall & Sullivan Inc. WA acquired a new stake in AbbVie in the 2nd quarter valued at approximately $25,000. Abound Financial LLC acquired a new stake in AbbVie in the 1st quarter valued at approximately $30,000. Cypress Capital Management LLC WY acquired a new stake in AbbVie in the 1st quarter valued at approximately $35,000. Finally, Inlight Wealth Management LLC acquired a new stake in AbbVie in the 1st quarter valued at approximately $42,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ABBV has been the topic of several analyst reports. JPMorgan Chase & Co. raised their target price on AbbVie from $200.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Wells Fargo & Company raised their target price on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. UBS Group set a $251.00 target price on AbbVie in a research report on Friday, October 3rd. Guggenheim increased their price target on AbbVie from $216.00 to $227.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Finally, Evercore ISI lifted their price target on AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research report on Monday, September 22nd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus price target of $231.90.

Check Out Our Latest Stock Analysis on ABBV

AbbVie Stock Down 0.1%

Shares of ABBV stock opened at $230.36 on Tuesday. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $244.81. The stock has a market cap of $406.94 billion, a PE ratio of 109.70, a price-to-earnings-growth ratio of 1.42 and a beta of 0.51. The business’s fifty day moving average is $215.50 and its 200-day moving average is $196.89. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $2.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.24 by ($0.27). The firm had revenue of $15.42 billion for the quarter, compared to analyst estimates of $14.93 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter last year, the business posted $2.65 earnings per share. Equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 14th. Stockholders of record on Wednesday, October 15th will be paid a dividend of $1.64 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $6.56 annualized dividend and a dividend yield of 2.8%. AbbVie’s dividend payout ratio (DPR) is currently 312.38%.

Insider Buying and Selling at AbbVie

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the sale, the executive vice president directly owned 177,292 shares of the company’s stock, valued at $35,178,278.64. This trade represents a 19.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Nicholas Donoghoe sold 13,295 shares of the firm’s stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total value of $2,639,190.45. Following the sale, the executive vice president directly owned 58,247 shares of the company’s stock, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.08% of the company’s stock.

AbbVie Profile

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.